Trial · NCT00410813
Adverse events154
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 154
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hemoglobin | Blood and lymphatic system disorders | Dasatinib, 100 mg, Daily | 16 | 41 | |
| other | Hemoglobin | Blood and lymphatic system disorders | Dasatinib, 70 mg, Twice Daily | 22 | 38 | |
| other | Constipation | Gastrointestinal disorders | Dasatinib, 100 mg, Daily | 8 | 41 | |
| other | Constipation | Gastrointestinal disorders | Dasatinib, 70 mg, Twice Daily | 3 | 38 | |
| other | Diarrhea | Gastrointestinal disorders | Dasatinib, 100 mg, Daily | 10 | 41 | |
| other | Diarrhea | Gastrointestinal disorders | Dasatinib, 70 mg, Twice Daily | 14 | 38 | |
| other | Dysphagia (difficulty swallowing) | Gastrointestinal disorders | Dasatinib, 100 mg, Daily | 1 | 41 | |
| other | Dysphagia (difficulty swallowing) | Gastrointestinal disorders | Dasatinib, 70 mg, Twice Daily | 2 | 38 | |
| other | Flatulence | Gastrointestinal disorders | Dasatinib, 100 mg, Daily | 3 | 41 | |
| other | Flatulence | Gastrointestinal disorders | Dasatinib, 70 mg, Twice Daily | 2 | 38 | |
| other | Heartburn/dyspepsia | Gastrointestinal disorders | Dasatinib, 100 mg, Daily | 4 | 41 | |
| other | Heartburn/dyspepsia | Gastrointestinal disorders | Dasatinib, 70 mg, Twice Daily | 1 | 38 | |
| other | Nausea | Gastrointestinal disorders | Dasatinib, 100 mg, Daily | 15 | 41 | |
| other | Nausea | Gastrointestinal disorders | Dasatinib, 70 mg, Twice Daily | 19 | 38 | |
| other | Vomiting | Gastrointestinal disorders | Dasatinib, 100 mg, Daily | 10 | 41 | |
| other | Vomiting | Gastrointestinal disorders | Dasatinib, 70 mg, Twice Daily | 8 | 38 | |
| other | Edema: head and neck | General disorders | Dasatinib, 100 mg, Daily | 1 | 41 | |
| other | Edema: head and neck | General disorders | Dasatinib, 70 mg, Twice Daily | 3 | 38 | |
| other | Edema: limb | General disorders | Dasatinib, 100 mg, Daily | 2 | 41 | |
| other | Edema: limb | General disorders | Dasatinib, 70 mg, Twice Daily | 6 | 38 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00410813/events